Beqalzi cleared for relapsed or refractory mantle cell lymphoma

What this means

Beqalzi is a targeted cancer drug that blocks BCL2, a protein that helps cancer cells survive, particularly in certain blood cancers. Today FDA approved Beqalzi for mantle cell lymphoma that has returned or stopped responding to other treatments. This gives patients with this aggressive cancer a new option that may work even when other BCL2 inhibitors have failed.